ロード中...
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the...
保存先:
| 出版年: | Blood Adv |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6960473/ https://ncbi.nlm.nih.gov/pubmed/31935286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000864 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|